These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 23824745)
1. Candidate tumor suppressor and pVHL partner Jade-1 binds and inhibits AKT in renal cell carcinoma. Zeng L; Bai M; Mittal AK; El-Jouni W; Zhou J; Cohen DM; Zhou MI; Cohen HT Cancer Res; 2013 Sep; 73(17):5371-80. PubMed ID: 23824745 [TBL] [Abstract][Full Text] [Related]
2. Regulation of receptor for activated C kinase 1 protein by the von Hippel-Lindau tumor suppressor in IGF-I-induced renal carcinoma cell invasiveness. He X; Wang J; Messing EM; Wu G Oncogene; 2011 Feb; 30(5):535-47. PubMed ID: 20871634 [TBL] [Abstract][Full Text] [Related]
3. PTEN suppression of YY1 induces HIF-2 activity in von-Hippel-Lindau-null renal-cell carcinoma. Petrella BL; Brinckerhoff CE Cancer Biol Ther; 2009 Jul; 8(14):1389-401. PubMed ID: 19483472 [TBL] [Abstract][Full Text] [Related]
4. Inhibitor of growth 4 inhibits cell proliferation, migration, and induces apoptosis of renal cell carcinoma cells. Sun J; Xie L; Lv J; Zhang W; Lv J; Liang Y; Geng Y; Li X J Cell Biochem; 2019 Apr; 120(4):6709-6717. PubMed ID: 30390334 [TBL] [Abstract][Full Text] [Related]
5. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293 [TBL] [Abstract][Full Text] [Related]
6. Identification of novel VHL target genes and relationship to hypoxic response pathways. Maina EN; Morris MR; Zatyka M; Raval RR; Banks RE; Richards FM; Johnson CM; Maher ER Oncogene; 2005 Jun; 24(28):4549-58. PubMed ID: 15824735 [TBL] [Abstract][Full Text] [Related]
7. Jade-1, a candidate renal tumor suppressor that promotes apoptosis. Zhou MI; Foy RL; Chitalia VC; Zhao J; Panchenko MV; Wang H; Cohen HT Proc Natl Acad Sci U S A; 2005 Aug; 102(31):11035-40. PubMed ID: 16046545 [TBL] [Abstract][Full Text] [Related]
8. Activation of the PI3K/AKT pathway induces urothelial carcinoma of the renal pelvis: identification in human tumors and confirmation in animal models. Qian CN; Furge KA; Knol J; Huang D; Chen J; Dykema KJ; Kort EJ; Massie A; Khoo SK; Vanden Beldt K; Resau JH; Anema J; Kahnoski RJ; Morreau H; Camparo P; Comperat E; Sibony M; Denoux Y; Molinie V; Vieillefond A; Eng C; Williams BO; Teh BT Cancer Res; 2009 Nov; 69(21):8256-64. PubMed ID: 19843858 [TBL] [Abstract][Full Text] [Related]
9. Hyperactivated JNK is a therapeutic target in pVHL-deficient renal cell carcinoma. An J; Liu H; Magyar CE; Guo Y; Veena MS; Srivatsan ES; Huang J; Rettig MB Cancer Res; 2013 Feb; 73(4):1374-85. PubMed ID: 23393199 [TBL] [Abstract][Full Text] [Related]
10. Induction of the Mdm2 gene and protein by kinase signaling pathways is repressed by the pVHL tumor suppressor. Mabry AR; Singh A; Mulrooney B; Gorman J; Thielbar AR; Wolf ER; Mayo LD Proc Natl Acad Sci U S A; 2024 Jul; 121(31):e2400935121. PubMed ID: 39047034 [TBL] [Abstract][Full Text] [Related]
11. Significance of PI3K signalling pathway in clear cell renal cell carcinoma in relation to VHL and HIF status. Tumkur Sitaram R; Landström M; Roos G; Ljungberg B J Clin Pathol; 2021 Apr; 74(4):216-222. PubMed ID: 32467322 [TBL] [Abstract][Full Text] [Related]
12. Jade-1: its structure, regulation and functions in the renal cancer. Zhang YC; Du WQ; Zhang RY; Zheng JN; Pei DS Curr Mol Med; 2016; 16(1):63-9. PubMed ID: 26695694 [TBL] [Abstract][Full Text] [Related]
13. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma. Perier A; Fregni G; Wittnebel S; Gad S; Allard M; Gervois N; Escudier B; Azzarone B; Caignard A Oncogene; 2011 Jun; 30(23):2622-32. PubMed ID: 21258414 [TBL] [Abstract][Full Text] [Related]
14. The von Hippel-Lindau protein sensitizes renal carcinoma cells to apoptotic stimuli through stabilization of BIM(EL). Guo Y; Schoell MC; Freeman RS Oncogene; 2009 Apr; 28(16):1864-74. PubMed ID: 19305426 [TBL] [Abstract][Full Text] [Related]
15. Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma. Thompson JM; Nguyen QH; Singh M; Pavesic MW; Nesterenko I; Nelson LJ; Liao AC; Razorenova OV Oncogene; 2017 Feb; 36(8):1080-1089. PubMed ID: 27841867 [TBL] [Abstract][Full Text] [Related]
16. von Hippel-Lindau protein promotes Skp2 destabilization on DNA damage. Roe JS; Kim HR; Hwang IY; Cho EJ; Youn HD Oncogene; 2011 Jul; 30(28):3127-38. PubMed ID: 21358672 [TBL] [Abstract][Full Text] [Related]
17. The von Hippel-Lindau tumor suppressor protein sensitizes renal cell carcinoma cells to tumor necrosis factor-induced cytotoxicity by suppressing the nuclear factor-kappaB-dependent antiapoptotic pathway. Qi H; Ohh M Cancer Res; 2003 Nov; 63(21):7076-80. PubMed ID: 14612498 [TBL] [Abstract][Full Text] [Related]
18. Renal cell carcinoma- and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones. Tsuchiya MI; Okuda H; Takaki Y; Baba M; Hirai S; Ohno S; Shuin T Oncol Rep; 2005 Jun; 13(6):1033-41. PubMed ID: 15870918 [TBL] [Abstract][Full Text] [Related]